Esketamine, brand name Spravato, is an FDA-approved nasal spray for depression that has been offering a breakthrough for individuals who are resistant to traditional therapies. Depression is one of the most common mental health conditions worldwide, but many individuals have had no response to other therapies and struggle to find relief––known as treatment-resistant depression (TRD). In addition, traditional therapies can take weeks or even months to show significant reduction in symptoms, leaving individuals feeling stuck and unmotivated to seek traditional alternatives.
Therefore, it is imperative that we consider what new innovative therapies can offer individuals who have found it challenging to find effective treatments options. This is where Spravato nasal spray for depression can offer new hope.
Spravato, esketamine, nasal spray for depression was developed to treat treatment-resistant depression (TRD) and is an enantiomer of ketamine––which has also been recently known for its rapid antidepressant effects in studies and practices. Unlike traditional antidepressants, ketamine and esketamine work by affecting the glutamate system in the brain that plays a major role in mood regulation, which is believed to be the cause of rapid antidepressant effects in just a matter of days. It is important to note that Ketamine and esketamine are commonly mistaken for one another and used interchangeably, despite being two distinct treatments.
Unlike Ketamine, Spravato was FDA-approved in 2019 for adults who have not had sufficient improvement in depression symptoms after trying at least two different oral antidepressants. This approval has paved a new avenue for those with TRD who are struggling all while also being able to receive coverage from insurance plans to be more accessible to those in need.
Who can Benefit from Spravato Nasal Spray for Depression?
Spravato treatment for treatment-resistant depression might not be for everyone, as every individual has different concerns and needs, but the medication can be highly effective for individuals who meet specific criteria:
1.Individuald who are considered treatment resistant
Individuals with Treatment-Resistant Depression (TRD) are the primary group that benefit from Spravato nasal spray. To be diagnosed with TRD you must already have a diagnosis in Major Depressive Disorder (MDD). MDD that does not respond to at least two different oral antidepressant medications would then be considered treatment-resistant. Not responding can be different for individuals: either over a period of time (around 4-6 weeks) there are no changes to symptoms or adverse side effects that cause medication shifts can be considered non-responsive. If you are interested in knowing more about treatment-resistant, it is important to speak with your current mental health provider. Or, reaching out to Spravato centers, such as Oasis Center, can help coordinate consultations with a psychiatrist to address your specific history and create unique treatment plans that fit your needs.
Spravato nasal spray for depression offers a faster-acting alternative when compared to traditional antidepressants that can take several weeks to show noticeable improvement. Studies have shown noticeable improvement in symptoms as early as the first 24-48 hours after the first treatment. Spravato nasal spray has thus been an attractive option for individuals who have found no relief from traditional medication and feel hopeless after trying numerous treatments with little success.
2.Patient who require Fast-Acting Relief
Individuals who are experiencing severe symptoms of depression, such as suicidal thoughts or feeling, have a hard time finding alternatives for treatment that can provide quicker relief. However, since Spravato has been approved, it has been a valuable tool in reducing the severity of depression episodes. This is due to esketamine acting on the brain’s glutamate receptors, believed to cause a significant improvement in mood and symptoms faster than traditional antidepressants. Additionally, as of 2025, Spravato esketamine nasal spray for depression has been approved as its monotherapy––it no longer requires individuals to be prescribed an oral antidepressant in conjunction. Thus, individuals who have tried multiple oral medications and have not reacted well with them do not have to continue taking their oral antidepressant medication. However, having a conversation with your current mental health professional about your options before stopping medication is important.
3.People who cannot tolerate Traditional Antidepressants
Common side effects of SSRI’s, SNRI’s, and other antidepressants include weight gain, sexual dysfunction, sleep disturbances, and gastrointestinal issues. For those who experience intolerable side effects, Spravato esketamine nasal spray can be a viable alternative.
4.Those with Chronic Depression
Chronic depression, also referred to as persistent depressive disorder (PDD), is characterized by ongoing, long-term depressive symptoms. For many individuals with chronic depression, traditional treatments may not provide lasting relief. Thus, Spravato nasal spray for depression can be a beneficial option for those dealing with persistent symptoms that don’t respond to conventional therapies. Breaking the cycle of chronic depression, providing an opportunity for patients to experience significant improvement in their mood and overall well-being.
5. Patients with Co-occuring Mental Health conditions
Researchers have recently been exploring the expansion of Spravato nasal spray for depression and its ability to be helpful for individuals with depression who suffer from co-occurring mental health conditions, such as anxiety and post-traumatic stress disorder (PTSD). Depression often coexists with other mental health conditions, making treatment complicated. Thus, for individuals with complex or comorbid health concerns, Spravato treatment-resistant depression therapy may provide a more comprehensive solution.
How Is Spravato Nasal Spray Administered?
Spravato nasal spray for depression is administered under the supervision of a healthcare provider in a certified treatment center. Patients are given the nasal spray in a controlled, clinical setting where they can be monitored for any potential side effects. Due to the nature of the drug, patients are required to remain in the office for a period of time after treatment to ensure they do not experience any adverse reactions. Spravato is often prescribed as part of a comprehensive treatment plan, which may include psychotherapy and other medications to address underlying mental health issues.
Spravato nasal spray for depression offers a promising treatment option for individuals who have not found relief through traditional antidepressant medications. Those suffering from treatment-resistant depression, chronic depression, or who require fast-acting relief may benefit from this breakthrough therapy.
If you or someone you know is considering Spravato treatment-resistant depression therapy, consult with a healthcare provider to determine whether it is the right treatment option. Oasis Center specializes in Spravato medication providing new hope for those struggling with persistent depression and looking for an effective depression treatment in Diamond Bar, CA. Trust our expert team to guide you on your journey to recovery with personalized care and insurance support. Spravato is FDA-approved and administered in our medical clinic under the supervision of Dr. Amr Beltagui. Feel like yourself again.
